Duke's McClellan: Changing Drug Development Policy From Outside FDA

In an interview, Margolis Center for Health Policy's Mark McClellan and Gregory Daniel talk about their recent move from Brookings to Duke, the breadth and impact of their work with FDA on drug development issues, and opportunities for potential future collaborations under PDUFA VI.

More from Approval Standards

More from Pathways & Standards